Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infection.

Abstract

In the era of increasing antibiotic resistance, development of new agents that could provide therapeutic options for difficult to treat pathogens is vital. Dalbavancin is a new lipoglycopeptide recently approved by the US FDA for the treatment of acute bacterial skin and skin structure infections. A derivative of the older glycopeptide class, chemical structure alterations resulted in a molecule with a similar mechanism of action, however, with a comparatively increased activity as reflected by organism MICs. These modifications also resulted in an antibiotic with distinctive properties that allow for once-weekly dosing in the treatment of Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus and drug resistant Streptococcus spp. As the first of these long acting compounds, understanding the pharmacokinetic and pharmacodynamic properties of agents like dalbavancin is essential for determining a place in therapy.

DOI: 10.1586/14787210.2015.995633

Cite this paper

@article{Leuthner2015DalbavancinF, title={Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infection.}, author={Kimberly D Leuthner and Angela Yuen and Yu Mao and Aryan Rahbar}, journal={Expert review of anti-infective therapy}, year={2015}, volume={13 2}, pages={149-59} }